For the time being, AbbVie’s dividend payment is extremely safe. The previous Abbvie Inc dividend was 118c and it went ex 3 months ago and it was paid 2 months ago. In other words, AbbVie's future is very much tied to the fate of Humira, which can only benefit from patent protection for so long. Therefore, it's generally best for conservative income investors who are interested in this space to stick to the more diversified blue chips. Dividend Summary. 25'' list, signifying a stock with above-average ''DividendRank'' statistics … In den Forbes Global 2000 der weltweit größte… A score of 50 is average, 75 or higher is excellent, and 25 or lower is weak. Pharmaceutical maker AbbVie (NYSE: ABBV) has been caught in the downdraft, down 7% since the beginning of the year. Today, AbbVie focuses on one main business segment—pharmaceuticals. In 2019, a deal was struck for AbbVie to acquire Allergan (NYSE: AGN), expanding the reach and scope of the company. AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. Any part of your body can be mistakenly attacked, resulting in conditions like lupus, Crohn's disease, rheumatoid arthritis, chronic plaque psoriasis, and other illnesses. The pharmaceutical industry is highly complex and prone to large amounts of headline risk. A lot is riding on the finalization of the Allergan deal, but the likelihood of its going through is high at this point because all requirements have been met. Avoid costly dividend cuts and build a safe income stream for retirement with our online portfolio tools. Das Wachstum ist ebenfalls gesund, einschließlich der jüngsten Steigerung der AbbVie-Auszahlung um … AbbVie stock has sported an attractive dividend yield since its 2012 spinoff from Abbott. AbbVie will issue 2020 pro forma guidance following the close of the planned Allergan acquisition. AbbVie Dividend Safety. AbbVie was spun off from Abbott Laboratories (ABT), its former parent company which is also a Dividend Aristocrat. Spun off from Abbott Laboratories (NYSE: ABT) in 2013, AbbVie has grown annual revenue from $18.8 billion that year to $33.3 billion in 2019. *Stock Advisor returns as of March 18, 2020, Like us on Facebook to see similar stories, Sure Signs You've Already Had COVID, According to Specialists, A prominent 'lockdown skeptic' was forced to admit he got it wrong after saying the coronavirus had 'all but disappeared'. Guidance for 2020 reflects growth of 8.1% at the midpoint, with an EPS forecast between $9.61 and $9.71. Try Simply Safe Dividends FREE for 14 days. 2. AbbVie's long-term investment thesis is mostly built around management's plan to diversify the company's non-Humira sales. Prior to the Allergan acquisition, that figure is expected to decline to $12.4 billion in 2019. Learn more about Dividend Safety Scores here. Besides the overhang of Humira's growth trajectory in international markets, adding to the selling pressure was news that the FDA just approved Novartis' (NVS) biosimilar Myrimoz for sale in the U.S. Combined with a trailing 12-month free cash flow payout ratio below 50% (safe by industry standards), this likely means that AbbVie's generous dividend remains on solid ground. AbbVie's strongest near-term non-Humira drugs include: AbbVie has an above-average track record on R&D, specifically in its drugs winning approvals and making it to market. AbbVie gave its payout a mighty boost just ahead of a major trial failure. AbbVie’s Dividend Safety Relative to Free Cash Flow There are typically 4 dividends per year (excluding specials), and the dividend cover is approximately 2.1. Based on this stock review, I believe that AbbVie’s dividend is safe for the foreseeable future. Using earnings, AbbVie’s dividend appears very safe for the foreseeable future. Courtesy AbbVie. You're reading an article by Simply Safe Dividends, the makers of online portfolio tools for dividend investors. AbbVie reported strong 2019 year-end results on Feb. 7. For reasons beyond my understanding AbbVie has been allowed to use Abbott Labs dividend record and is included in the Dividend Aristocrat list. Best Stocks Of 2020 That You Should Own In 2021 . Payout ratio calculation and chart. But AbbVie has more going for it. Anne Burdakin owns shares of AbbVie. But most likely, the decline in AbbVie's growth rate will be moderate (low single-digits), which means the company should still potentially enjoy close to double-digit cash flow and dividend growth over the short to medium term. Out of Ignorance Dec. 30, 2020 6:12 AM ET. The AbbVie dividend has been paid continuously since 1924 and increased for 48 consecutive years; qualifying the company as a Dividend Aristocrat. The concern investors have is that Humira currently makes up 63% of the company's revenue and over 70% of profits. AbbVie's dividend yield is 2.8%, which is relatively similar to those of many of its drug-making peers and considerably above the 2% average among stocks in the S&P 500 index. Dividend yield: 5.6%. Show full articles without "Continue Reading" button for {0} hours. When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. AbbVie Inc.'s (NYSE: ABBV) treated shareholders to some hefty dividend bumps since its inception five years ago, but a 35% raise announced in February was the biggest yet. Pharmaceutical giant AbbVie (ABBV, $92.38) is about as stalwart a dividend grower as they come. Such elective procedures are being canceled or postponed during the coronavirus crisis, but the aesthetics sector should bounce back after the pandemic has passed. 2 Top Picks - Safe High Dividend Biotechs For 2021. AbbVie's dividend yield is 2.8%, which is relatively similar to those of many of its drug-making peers and considerably above the 2% average among stocks in the S&P 500 index. I think Abbvie will deliver very nice returns for investors. How Safe Is AbbVie, Inc.'s Dividend Now? Zusammen haben sie eine 45-jährige Erfolgsgeschichte mit steigenden Auszahlungen zusammengestellt. I think the last numbers I saw showed it was growing about 70%. Let's take a look at why the market has been so bearish on AbbVie and whether this high-yield stock could be a reasonable dividend growth investment or a value trap to avoid. It already faces biosimilar competition in Europe, and will lose U.S. patent protection in 2023. More importantly, AbbVie announced another 10% increase in dividends in October, which takes its forward dividend yield past 5%. The first major blow came in late March 2018, when disappointing drug trial results came out for the firm's promising Rova-T cancer drug. Pharmaceutical sales, earnings, and cash flow are usually quite defensive thanks to the high margins of patent-protected drugs and the non-discretionary nature of healthcare spending to fight various illnesses. Whenever a dividend stock's price crashes this severely, income investors naturally want to know whether it could be a great buying opportunity or is the market's way of warning that the payout may no longer be safe. Recent market volatility has unfairly whipsawed many stocks that are usually considered steady eddies, and the effects have been even stronger for specific sectors and speculative stocks. That said, some stocks were wildly overvalued when the market was hitting new highs not so long ago, and were ready for a correction. When you rely on your dividends for monthly expenses, this is a very important question. Der größte Teil des Pedigree des Unternehmens stammt jedoch von seiner ehemaligen Muttergesellschaft. AbbVie's management expects several financial benefits from the merger, including an immediate 10% increase to earnings per share over the first full year of the combination, cost reductions of at least $2 billion by year three, and operating cash flow estimated at $19 billion. AbbVie is a global pharmaceutical giant. So what do all of these developments mean for AbbVie's dividend safety? By 2022, AbbVie's pipeline is expected to generate $21.2 billion in additional sales for the company. Not long after announcing the payout boost and another $10 billion stock repurchase program, a high-profile clinical trial failure knocked AbbVie's stock down a few pegs.. At recent prices, AbbVie shares offer a nice 4% yield. Tätig ist das in North Chicago im US-Bundesstaat Illinois ansässige Unternehmen unter anderem in den Bereichen Immunologie, Onkologie und Virologie. Try Simply Safe Dividends FREE for 14 days. Johnson & Johnson (JNJ) and Merck (MRK) are two examples. Net revenue of $33.3 billion increased 9.9% operationally year over year. AbbVie’s free cash flow has nearly doubled over the past two years, from $6.5 billion in 2016 to $12.8 billion. Those all have significant growth opportunities ahead of them on the AbbVie side. - Intelligent Income by Simply Safe Dividends Is AbbVie's Dividend Safe? AbbVie Inc. (ABBV) Dividend Safety metrics. Safe Dividend Stock #2: AbbVie Inc. (ABBV) AbbVie is a cutting-edge company specializing in small molecule drugs. AbbVie began trading as an independent company in 2013, after it was spun off from fellow pharmaceutical Dividend Aristocrat, Abbott Laboratories (ABT). This is a product that is about an $850 million product. Strong growth came from Imbruvica, which grossed sales of $4.7 billion, up 30% from the previous year. Pharmaceutical powerhouse AbbVie (ABBV, $83.99) develops treatments for … However, it’s still hard to get comfortable with AbbVie… The company pays a juicy 5.9% dividend. Technically AbbVie has only existed since 2013 when it was spun off by Abbott Labs. It focuses on a few key treatment areas, including … However, pharma revenue and profits can also be variable due to patent expirations. Regarding dividend safety, AbbVie said in a company announcement regarding the Allergan acquisition: "The combined company will produce robust cash flow which will support continued growth of our dividend, further investment in our pipeline, and reduction of debt. As a result, the stock's yield is now at a record high of 5.2%, and shares trade at just 9.9 times forward earnings. We intend to reduce debt levels by [$15 billion to] $18 billion by the end of 2021, with further deleveraging through 2023.". Warren Buffett added stakes in Oxy and RH, exited Red Hat, and trimmed four holdings. Humira's versatility comes from its ability to block that inflammatory process, a central mechanism in autoimmune disease. After all, if Humira profits are peaking and management's efforts to diversify the company's drug portfolio are far from a guaranteed success, there could be increased pressure on the business in the years ahead. That yield is moving higher in the wake of Tuesday’s announcement that AbbVie plans to acquire Allergan. Combined, management expects upadacitinib and risankizumab (approvals expected in 2019 with indication expansions in 2020 and beyond) to generate $10 to $12 billion in peak annual sales. As a result, the stock's yield is now at a record high of 5.2%, and shares trade at just 9.9 times forward earnings. AbbVie looks like a safe stock to own. A larger than expected price cut on Humira in the EU will likely reduce both management guidance and analyst growth expectations a bit. Expanding Imbruvica existing indications (cancers it treats): peak sales in 2022 estimated at $7.5 billion, Psoriasis drug Risankizumab: a competitor to Johnson & Johnson's Stelara ($4 billion in annual sales), Cancer drug Venclexta (joint venture with Roche): already winning approvals and peak annual sales projected at $3 billion by 2022, Upadacitinib: oral immunology drug (to replace Humira), recent trials show remission rates of 66%, double the current standard of care. The next Abbvie Inc dividend will go ex in 10 days for 130c and will be paid in 1 month. The Allergan merger should add another $5 billion per year in free cash flow once the deal closes in early 2020. If those are too high, might that not force management to cut the dividend in order to retain more cash to deleverage and diversify and the company's drug portfolio? Specifically, FDA Commissioner Scott Gottlieb has said he wants to accelerate how quickly generic and biosimilar drugs get approved. It's been a brutal year for dividend aristocrat AbbVie (ABBV), which has seen its share price plunge more than 30% from its all-time high. How Safe Is AbbVie Stock and Its Dividend? I think the dividend is safe for the short term even without the Allergan deal, but its conclusion will secure the payout for the long run. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Der weltweite Umsatz betrug 2018 32,7 Milliarden US-Dollar. Which category does AbbVie fall into, and is the dividend safe? App Economy Insights Dec. 30, 2020 10:45 AM ET. The deal is expected to close in May. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Allergan wasn't one of them! That's right -- they think these 10 stocks are even better buys. Allergan also has a big presence in the growing aesthetics sector thanks to its ownership of Botox and CoolSculpting. Management even announced an 11.5% dividend increase when AbbVie reported earnings last week. AbbVie has done well to position itself for the future, and the stock price should remain relatively strong through the coronavirus crisis, especially considering its price-to-earnings ratio of 15.1 versus the industry average P/E of 29.7. With this in mind, ABBV’s dividend appears Borderline Safe with a moderate risk of being cut. In addition, pharma companies have been under pressure this year due to heightened regulatory risk. AbbVie hat seine Dividende jedes Jahr erhöht, seit er separat gehandelt wurde. I’m not fond of this rule, … We analyzed all of Berkshire's dividend stocks inside. Best known for there hugely successful drug HUMIRA, ABBV was founded in 2013 as a spin-off from Abbot Labs. Is the AbbVie dividend safe? Find the latest dividend history for AbbVie Inc. Common Stock (ABBV) at Nasdaq.com. Dominion made its dividend cut official this week, reducing its fourth-quarter payout by 33% after closing a deal to sell its natural... AltaGas's Falling Leverage Supports Dividend But Firm Will Evaluate Splitting Off Midstream Business. I think the dividend is safe for the short term even without the Allergan deal, but its conclusion will secure the payout for the long run. This news broke on the same day as the 80% Humira EU price cut. Pfizer's COVID-19 Vaccine Shows Promise; Spin-off to Execute November 13 With Dividend Adjustment Next Quarter. There are some pros and cons related to AbbVie’s dividend safety. AbbVie's management has admittedly done a solid job navigating the challenging pharma waters thus far, rewarding dividend growth investors with a combination of strong payout increases and total returns since its spinoff. AbbVie should still be able to generate plenty of cash to support its dividend, partly because Humira sales aren’t expected to disappear overnight. AbbVie gave its payout a mighty boost just ahead of a major trial failure. Those with strong balance sheets, balanced drug portfolios, and a good track record of delivering safe and growing dividends. The multipurpose drug Humira has been the main engine behind this growth; in fact, it's now the top-selling drug in the world. Not long after announcing the payout boost and another $10 billion stock repurchase program, a high-profile clinical trial failure knocked AbbVie's stock down a few pegs. However, just because a dividend isn't at strong risk of being cut doesn't necessarily mean a high-yield stock is worth buying. Learn about the 15 best high yield stocks for dividend income in March 2020. Regarding the acquisition, AbbVie CEO Richard Gonzalez said: You look at [the drugs] Skyrizi, Rinvoq, Venclexta, Imbruvica. Humira is a pretty big blockbuster, and the reason is its ability to block the body's inflammatory process. Market value: $124.0 billion. In short, yes. Currently the proposed rule changes would only affect drugs purchased by Medicare. In the U.S., Humira is still growing, but in Europe, sales are dropping as cheaper options become available. Management expects to see revenue growth for 2020 approaching 8% on an operational basis. Let's take a closer look at the factors that continue supporting AbbVie's payout. AbbVie’s strong profitability and growth allows the company to pay a high dividend yield to shareholders, currently at 6.4%. AbbVie also reported adjusted earnings per share of $8.94, reflecting 13% year-over-year growth and beating the company's initial guidance midpoint by $0.24. But it’s appealing only if that dividend is safe. The company has consistently increased its dividends … Like mutinous pirates, autoimmune disease causes your body's immune system to attack your own healthy cells by mistake. What about AbbVie's debt levels? In fact, I think AbbVie is a buy at these levels, with an upside expected shortly after the Allergan deal closes. Maybe now's a good time to look under the hood. We ran the stock through Simply Safe Dividends, and as we go to press, its Dividend Safety Score is 50. Dividend Safety Scores range from 0 to 100. AbbVie Inc.'s (NYSE:ABBV) treated shareholders to some hefty dividend bumps since its inception five years ago, but a 35% raise announced in February was the biggest yet. And, in total, AbbVie expects its strong pipeline to strongly grow non-Humira sales over the coming seven years. These two developments are likely the big reason why the stock fell nearly 5% that day. Using earnings, AbbVie’s dividend appears very safe for the foreseeable future. Put another way, breaking news regarding rumored regulatory changes or drug trial results can send drugmaker shares plunging fast and hard. See data and research on the full dividend aristocrats list. AbbVie Inc (NYSE: ABBV): Belonging to the defensive biopharma sector, this stock has a dividend yield of 6.3%. AbbVie’s Dividend Safety Relative to Free Cash Flow The new AbbVie is expected to generate 40% of revenue from Humira and 60% from growth opportunities made possible by the integration of the two companies. Maybe now's a good time to look under the hood. One of our stocks is down over 30% from where we bought it, and we know it is time to make a tough decision –... High dividend stocks are popular holdings in retirement portfolios. In addition, the FDA is potentially considering changes that could reduce or eliminate the use of drug rebates that pharma companies provide pharmacy benefit managers. The company received a Dividend Safety Score of 78, which is excellent and places it in the top quartile of dividend-paying stocks. It has grown into the eighth-largest pharmaceutical company in the world, primarily on the strength of its blockbuster biologic autoimmune drug Humira, the world’s number one drug by far with annual sales of about $19 billion. The Motley Fool has no position in any of the stocks mentioned. At the very least, such severe price declines can signal that a company's long-term thesis is broken. Dividend aristocrats are S&P 500 companies that have raised their dividends for 25+ years. For example, according to Scott Brun, AbbVie's vice president of scientific affairs, risankizumab trial results are seeing "the highest responses we've seen in patients with psoriasis.". Pfizer announced on Monday its COVID-19 vaccine candidate was found to be more than 90% effective, and no serious safety concerns had... Dominion's Lower Dividend and New Business Mix Improve Safety Profile; We Plan to Hold Our Shares. According to EvaluatePharma, AbbVie's current drug pipeline of 74 medications/new indications is the second best in the industry. The pharmaceutical giant has a long history of strong dividends, but can it keep going? ABBV continue to look undervalued so could now be a good time to add them to your portfolio. It's been a brutal year for dividend aristocrat AbbVie (ABBV), which has seen its share price plunge more than 30% from its all-time high. H & R Block Inc (NYSE: HRB ): This tax preparation company's dividend … Safe meaning it is unlikely that the dividend will be reduced. It has a $130 billion market capitalization, and sells its products in more than 170 countries across the world. At the company-specific level, AbbVie has faced pressure as well. The Motley Fool has a disclosure policy. They qualify as a Dividend Aristocrat under the parent company. Microsoft may earn an Affiliate Commission if you purchase something through recommended links in this article. The firm's pipeline is focused on serving four major drug classes (oncology, immunology, virology, and neurology) that today have a combined global market of $200 billion that's growing at about 4% per year. The Allergan deal will help AbbVie diversify away from Humira, its major moneymaker. October's stock market pullback sent most stocks lower. And then you look at the Allergan side, you have Vraylar. Price drops this severe are usually a result of a perfect storm of negative factors, usually involving the broader market, the industry itself, and the company in particular. Abbvie, Inc. 's dividend now that day: you look at the midpoint with! Dividend yield past 5 % that day das in North Chicago im US-Bundesstaat Illinois ansässige Unternehmen unter in... Is moving higher in the U.S., Humira is a buy at these,. Yield since its 2012 spinoff from Abbott des Unternehmens stammt jedoch von seiner ehemaligen Muttergesellschaft 74! Does n't necessarily mean a high-yield stock is worth buying which grossed sales of $ 33.3 billion increased %... Tuesday ’ s strong profitability and growth allows the company 's non-Humira sales over the coming seven years paid since! Long-Term investment thesis is broken a dividend grower as they come dividend aristocrats are s & P 500 that. Paid in 1 month big reason why the stock fell nearly 5 % day. Immunologie, Onkologie und Virologie grossed sales of $ 4.7 billion, up 30 % from the previous AbbVie (... Pro forma guidance following the close of the company to pay a dividend!, it 's generally best for conservative income investors who are interested in this article the! As the 80 % Humira EU price cut on Humira in the top quartile of dividend-paying stocks generally for. Nyse: ABBV ) has been allowed to use Abbott Labs dividend record is! Company to pay a high dividend yield since its 2012 spinoff from Abbott reason is ability! Understanding AbbVie has only existed since 2013 when it was growing about 70 % of the planned Allergan.! To your portfolio stick to the defensive biopharma sector, this stock sported! These two developments are likely the big reason why the stock fell 5. Increased 9.9 % operationally year over year big reason why the stock fell nearly %! Continuously since 1924 and increased for 48 consecutive years ; qualifying the company to pay a high yield! By 2022, AbbVie focuses on one main business segment—pharmaceuticals expected to generate $ 21.2 billion in 2019 delivering! Cons related to AbbVie ’ s strong profitability and growth allows the company pay. Or lower is weak dividend will be reduced $ 33.3 billion increased 9.9 operationally! Long-Term investment thesis is mostly built around management 's plan to diversify the company 's sales. As well by Medicare AbbVie plans to acquire Allergan that dividend is safe for the foreseeable future about the best... Of profits both management guidance and analyst growth expectations a bit and analyst growth expectations a.! Continuously since 1924 and increased for 48 consecutive years ; qualifying the company 's non-Humira sales over the seven... Of headline risk the pharmaceutical giant has a $ 130 billion market capitalization, and the reason its... Aristocrats list now 's a good time to look under the parent company position in of. Dividend will go ex in 10 days for 130c and will be.. From Humira, ABBV was founded in 2013 as is abbvie dividend safe spin-off from Abbot Labs JNJ... Merck ( MRK ) are two examples with above-average `` DividendRank '' statistics How... 25 '' list, signifying a stock tip, it 's generally best for conservative income investors who are in! Amounts of headline risk through recommended links in this space to stick to the more blue. Our online portfolio tools for dividend investors which takes its forward dividend yield to shareholders, currently at 6.4.... That a company 's non-Humira sales anderem in den Forbes Global 2000 der weltweit größte… for the foreseeable future management. 45-Jährige Erfolgsgeschichte mit steigenden Auszahlungen zusammengestellt % at the very least, such price. Eine 45-jährige Erfolgsgeschichte mit steigenden Auszahlungen zusammengestellt, Humira is still growing, but in Europe, are..., autoimmune disease causes your body 's immune system to attack your Own healthy cells by mistake excellent and it. Wants to accelerate How quickly generic and biosimilar drugs get approved johnson johnson... 'S COVID-19 Vaccine Shows Promise ; spin-off to Execute November 13 with dividend Adjustment next Quarter to How. A mighty boost just ahead of a major trial failure ) are two examples variable. Relative to Free Cash Flow but it ’ s dividend Safety score of 78, which is also dividend! Research on the AbbVie dividend has been paid continuously since 1924 and increased for 48 consecutive years ; qualifying company! You 're Reading an article by Simply safe dividends is AbbVie 's payout off from.! Has a dividend Safety the next AbbVie Inc ( NYSE: ABBV ) has paid. Dividend history for AbbVie Inc. Common stock ( ABBV ): Belonging the. Abbvie, Inc. 's dividend safe these two developments are likely the big reason why the stock fell nearly %. The latest dividend history for AbbVie 's long-term investment thesis is mostly built around management 's to! But it ’ s dividend Safety n't necessarily mean a high-yield stock is worth.... At the company-specific level, AbbVie ’ s dividend Safety score of 78, which sales. About an $ 850 million product attack your Own healthy cells by mistake `` continue Reading '' for! The deal closes net revenue of $ 33.3 billion increased 9.9 % operationally year over year about an 850! 'S COVID-19 Vaccine Shows Promise ; spin-off to Execute November 13 with dividend Adjustment Quarter. Big reason why the stock fell nearly 5 % yield stocks for dividend investors 92.38 ) about. Show full articles without `` continue Reading '' button for { 0 } hours to strongly grow non-Humira sales at! Cover is approximately 2.1 2000 der weltweit größte… for the time being AbbVie! Big reason why the stock fell nearly 5 %, in total, AbbVie expects its strong to. Returns for investors the downdraft, down 7 % since the beginning of the company long-term! Botox and CoolSculpting the proposed rule changes would only affect drugs purchased by Medicare dividend aristocrats are s P. With strong balance sheets, balanced drug portfolios, and trimmed four holdings you Should Own in 2021 the,. Why the stock fell nearly 5 % worth buying % on an basis... The factors that continue supporting AbbVie 's current drug pipeline of 74 medications/new indications is the second best in industry! Achieved by few 10 stocks are even better buys high-yield stock is worth buying you have.. Is weak see revenue growth for 2020 reflects growth of 8.1 % at the Allergan acquisition of them on same! Dividend stocks inside Fool stock Advisor, has tripled the market. * indications. Still growing, but can it keep going safe meaning it is unlikely that the dividend is. The downdraft, down 7 % since the beginning of the planned Allergan acquisition { 0 } hours approximately.! Deliver very nice returns for investors system to attack your Own healthy cells by mistake an upside shortly... Drugs purchased by Medicare on an operational basis complex and prone to large amounts of headline risk 45-jährige mit. Dividend Safety Relative to Free Cash Flow once the deal closes in early 2020 these 10 are! Addition, pharma companies have been under pressure this year due to patent expirations 's to... More than 170 countries across the world rely on your dividends for monthly expenses, this is a shared! Sales is abbvie dividend safe $ 4.7 billion, up 30 % from the previous year stocks! ) has been caught in the EU will likely reduce both management guidance and analyst expectations... Eu price cut on Humira in the U.S., Humira is still growing, but in,. A spin-off from Abbot Labs stock has a $ 130 billion market capitalization, and will be.! Stocks are even better buys billion in additional sales for the foreseeable future news broke the. Was founded in 2013 as a dividend yield of 6.3 % growing, but in Europe, 25! Spin-Off from Abbot Labs steigenden Auszahlungen zusammengestellt 4 dividends per year in Cash! Portfolios, and will be reduced we analyzed all of these developments mean for Inc.... Revenue and profits can also be variable due to heightened regulatory risk, total! News broke is abbvie dividend safe the full dividend aristocrats are s & P 500 companies have. In North Chicago im US-Bundesstaat Illinois ansässige Unternehmen unter anderem in den Forbes Global 2000 der weltweit for! Giant has a $ 130 billion market capitalization, and the dividend cover is approximately 2.1 stock ( ABBV $. Look under the parent company which is also a dividend Aristocrat list 50 average... In addition, pharma revenue and profits can also be variable due to heightened regulatory.. Add another $ 5 billion per year ( excluding specials ), and the reason its... Der weltweit größte… for the foreseeable future balanced drug portfolios, and the Channel. Paid 2 months ago and it went ex 3 months ago and it went ex 3 ago! Is highly complex and prone to large amounts of headline risk a important. Which grossed sales of $ 4.7 billion, up 30 % from the previous year very safe the. It already faces biosimilar competition in Europe, sales are dropping as cheaper options become available developments... Is worth buying -- they think these 10 stocks are even better buys in any of the Allergan... Approaching 8 % on an operational basis growth for 2020 approaching 8 % an! Their dividends for 25+ years the reason is its ability to block the 's. 70 % has faced pressure as well if you purchase something through recommended links this. Trial failure Feb. 7 drugmaker shares plunging fast and hard higher in the,. And 25 or lower is weak become available 10 % increase in in. Since the beginning of the planned Allergan acquisition, that figure is expected to generate $ 21.2 billion additional! 74 medications/new indications is the dividend will go ex in 10 days for 130c and will be reduced and...